1. Scope

This summary covers evidence-based and emerging strategies to preserve cognition and reduce the risk of Alzheimer’s disease and related dementias (ADRD) in adults who are cognitively normal or have subjective/mild cognitive impairment (MCI), delivered in an independent longevity clinic as an adjunct to conventional primary and secondary care.

Covered: multidomain lifestyle intervention; vascular/metabolic risk-factor control; sensory (hearing) optimisation; sleep; nutrition and supplements (B vitamins, omega-3, vitamin D); off-label geroscience agents (metformin, GLP-1 receptor agonists, rapamycin, NAD⁺ precursors, senolytics); and blood/imaging biomarkers for risk stratification.

Not covered: diagnosis and disease-modifying treatment of established dementia (e.g. anti-amyloid monoclonal antibodies lecanemab/donanemab, which are licensed only for MCI/mild dementia due to Alzheimer’s disease and are secondary-care therapies); management of Parkinson’s disease, frontotemporal dementia and other specific neurodegenerative diagnoses.[1]

This document is intended as expert-consensus guidance framed around the highest available evidence. Several interventions discussed are off-label or research-grade and are flagged as such.

2. Background and pathophysiology

Ageing is the dominant risk factor for neurodegeneration. Neurodegenerative disease has a long (often decades-long) preclinical phase in which pathology accumulates before symptoms, providing a prevention window.[2]

Biologically plausible, partly human-validated mechanisms relevant to longevity practice:

– Vascular/neurovascular injury – hypertension, dyslipidaemia, diabetes and small-vessel disease drive white-matter damage and contribute to both vascular and Alzheimer-type dementia.[3][4]

– Amyloid-β and tau pathology – detectable via plasma p-tau217, Aβ42/40 15–20 years before symptoms.[5][2]

– Neuroinflammation and cellular senescence – accumulating senescent glia produce a senescence-associated secretory phenotype driving chronic neuroinflammation.[6][7]

– Impaired metabolic/nutrient-sensing signalling – mTOR, AMPK, sirtuin and autophagy pathways; mitochondrial dysfunction and NAD⁺ decline.[8][9]

– Circadian/glymphatic clearance – slow-wave sleep supports glymphatic clearance of Aβ and tau.[10]

Preclinical only (mechanistic plausibility, no robust human cognitive outcome data): NAD⁺ precursors reduce neuroinflammation and senescence via cGAS-STING in transgenic AD mice; senolytics (dasatinib, quercetin, fisetin) clear senescent cells and improve cognition in rodent models; rapamycin, resveratrol, spermidine and metformin are neuroprotective in animal models of neurodegeneration.[11][6][7][12][13][14] These findings should not be extrapolated to human clinical benefit.

3. Evidence base and grading

The evidence for prevention is dominated by prospective cohort studies and a smaller number of multidomain RCTs; single-agent pharmacological prevention trials are largely negative or inconclusive. GRADE-style certainty and recommendation strengths follow.

Intervention	Key outcome	Evidence statement & certainty	Recommendation	References
Multidomain lifestyle (diet, exercise, cognitive training, vascular monitoring)	Global cognition	FINGER RCT (n=1,260) showed improved cognition over 2 yrs; US POINTER confirmed benefit; SMARRT and Brodaty online RCT positive. Moderate (indirectness: cognition not dementia incidence)	Strong (offer)	[3], [4], [15], [16]
Physical activity	Incident dementia	SR/MA of cohorts (n≈2.9M) RR 0.75; prolonged sitting RR 1.27. Moderate	Strong (offer)	[17]
Intensive BP control (SBP <120)	MCI / MCI+dementia	SPRINT MIND RCT: significant reduction in MCI and composite; probable dementia (primary) not significant. Moderate	Strong (offer, individualised target)	[3], [4]
Hearing aids for hearing loss	Cognitive decline/dementia	Observational MA HR 0.81; ACHIEVE RCT benefit only in high-risk subgroup; ASPREE analysis dementia risk ~33% lower but little effect on overall cognition. Low–Moderate	Conditional (offer, esp. higher-risk)	[18], [19], [20]
Sleep optimisation (7–8 h)	Incident dementia	Cohort MA: short (<7h) RR 1.18, long (>8h) RR 1.28. Low (observational, reverse causation)	Conditional (offer)	[17]
MIND/Mediterranean diet	Dementia / cognition	Observational MA reduced risk; MIND RCT no effect on cognition/MRI. Low	Conditional (offer)	[21], [22]
B vitamins (folate, B12, B6)	Cognitive decline / brain atrophy	VITACOG RCT slowed atrophy in MCI with raised homocysteine; MA modest effect, chiefly with elevated homocysteine and long duration; negative in established AD. Low	Conditional (only if elevated homocysteine)	[23], [24], [25], [26]
Omega-3 (DHA/EPA)	Cognitive decline	Cohort MA ~20% lower risk; RCTs (DO-HEALTH, VITAL) negative in unselected older adults. Low	Conditional / only in research for prevention	[27], [28], [29]
Vitamin D	Cognitive decline	VITAL/DO-HEALTH RCTs no benefit in replete adults. Moderate (no effect)	Recommend against (for cognition; treat deficiency on its own merits)	[28], [30]
GLP-1 receptor agonists	Dementia	RCT MA (GLP-1RA subgroup) OR 0.55; target-trial emulations HR ~0.67–0.80; dedicated AD RCT (evoke) reported. Low–Moderate, only in T2D/obesity populations	Conditional in licensed metabolic indications; off-label for cognition	[31], [32], [33]
Metformin	Cognitive impairment	Mixed observational/MA data; RCTs ongoing (geroscience). Very low for cognition	Only in research (off-label)	[8], [21]
NAD⁺ precursors (NR/NMN)	Cognition	Human data limited and mixed; no cognitive-outcome RCTs. Very low	Only in research	[8], [13]
Senolytics (D+Q, fisetin)	Neurodegeneration	Preclinical only; early-phase human trials underway; dose-limiting toxicity (e.g. thrombocytopenia). Very low	Only in research	[6], [7], [8]
Rapamycin	Cognition/dementia	Animal data only; no human cognitive-outcome trials. Very low	Only in research (off-label)	[12], [13], [34]

Cross-cutting limitations: cohort evidence carries confounding and reverse-causation risk; multidomain RCTs use surrogate cognitive composites rather than dementia incidence (indirectness), have practice effects in controls, and short follow-up; heterogeneity in physical-activity and diet meta-analyses is substantial. Publication bias is a concern for supplement literature. The Lancet Commission estimates ~40% of dementia is attributable to 14 modifiable factors, but this is a population-attributable estimate, not proof of individual-level preventability.[4]

4. Patient selection and indications

Candidates most likely to benefit:

– Midlife and older adults (≈40–75) with modifiable cardiometabolic risk – hypertension, dyslipidaemia (raised LDL-C), type 2 diabetes/insulin resistance, obesity, smoking, physical inactivity. Highest absolute benefit where risk-factor burden is greatest.[4][22]

– APOE ε4 carriers or those with a family history – lifestyle benefit persists even in high polygenic-risk and ε4 groups.[35][22]

– Adults with subjective cognitive decline (SCD) or MCI – biomarker-based risk stratification (below) is most informative here.[36]

– Individuals with untreated hearing loss, poor sleep, depression, or low cognitive/social engagement.[4]

Exclusion / specialist-input groups:

– Established dementia (refer to memory services; anti-amyloid therapy is secondary care).[1]

– Frailty and advanced multimorbidity – intensive BP targets and aggressive supplement/drug regimens may cause harm; individualise.

– Any off-label geroscience agent outside a trial in patients who cannot give fully informed consent.

Regulatory/ethical status:

– On-label: BP, lipid, glucose and hearing management following NICE/specialty guidance; treating vitamin/homocysteine abnormalities.

– Off-label: metformin, GLP-1RA, rapamycin for cognitive indications; SGLT2i for cognition.

– Only in research / registry: senolytics, NAD⁺ precursors, rapamycin, epigenetic reprogramming. These should be delivered within trial frameworks or, at minimum, with documented informed consent that clearly states the absence of robust human efficacy data.[8][13]

5. Assessment and baseline work-up

History and examination:

– Full vascular/metabolic risk history, medication review (anticholinergic burden, benzodiazepines), alcohol, smoking, sleep (including OSA screening), mood, hearing/vision, physical activity, education/cognitive engagement, family history.

– Baseline cognitive testing (e.g. MoCA) and a validated functional/frailty measure in older adults.

Baseline investigations:

– Bloods: HbA1c/fasting glucose, lipid profile, U&E, LFTs, TFTs, FBC, B12, folate, homocysteine, vitamin D, HbA1c.

– BP (ideally ambulatory), BMI/waist.

– Formal audiometry where hearing loss suspected.[18]

– APOE genotyping only with pre-test counselling and consent.

– Emerging biomarkers (interpret cautiously, ideally in SCD/MCI): plasma p-tau217 (best-performing early AD marker; C-index ~0.86 alone, ~0.91 combined with memory tests and APOE), Aβ42/40, and neurodegeneration markers NfL/GFAP. Assays are not yet standardised for asymptomatic screening.[36][5][37][2]

– Structural MRI (hippocampal volume, white-matter hyperintensities) adds value for all-cause dementia risk and is warranted if symptomatic or biomarker-positive.[36]

Risk stratification: combine vascular risk burden, APOE status, cognitive testing and (where used) plasma p-tau217 to stratify low / moderate / high risk. Do not infer disease from a single surrogate biomarker; biomarker positivity in an asymptomatic person indicates increased risk, not diagnosis.

Baseline documentation: cognitive composite, BP, HbA1c, lipids, homocysteine, weight, hearing status, and any biomarker values, to allow meaningful longitudinal comparison.

6. Dosing regimens and practical implementation

Robust human-data interventions:

– Aerobic + resistance exercise: ≥150 min/week moderate aerobic activity plus resistance training ≥2×/week; reduce prolonged sitting (<8 h/day).[17]

– Multidomain programme (FINGER model): structured diet (Mediterranean/MIND pattern), supervised exercise, cognitive training, and active vascular/metabolic monitoring — the combination, not any single element, carries RCT support.[15][3]

– Blood pressure: treat per guideline; an intensive SBP target (~<120–130 mmHg) reduces MCI risk but requires monitoring for hypotension, AKI and falls, and modest brain-volume changes were noted in SPRINT.[3]

– Hearing aids: fit and encourage consistent daily use in those with audiometric hearing loss; benefit is greatest in higher-risk individuals.[19][18]

– Sleep: target 7–8 h; treat OSA.[17]

Nutrition/supplements (conditional):

– B vitamins (e.g. folic acid 0.8 mg, B12 0.5 mg, B6 20 mg/day as used in VITACOG) — consider only where homocysteine is elevated; benefit is on brain atrophy in MCI, with inconsistent cognitive translation and no benefit in established AD.[24][23][26]

– Omega-3 (DHA-predominant) — cohort-supported but RCT-negative in replete/unselected adults; reasonable dietary emphasis rather than routine high-dose supplementation.[27][28]

Extrapolated / caution (early-phase or preclinical — use only in research or licensed metabolic indications):

– GLP-1RA (e.g. semaglutide) — use for licensed diabetes/obesity/CV indications where cognitive benefit is a plausible ancillary effect; not established as a stand-alone cognitive preventive.[31][33]

– Metformin, rapamycin, NAD⁺ precursors, senolytics — no validated cognitive-prevention dosing; do not initiate for cognition outside trials. Senolytics carry dose-limiting toxicity (thrombocytopenia).[6][8]

7. Monitoring, safety and follow-up

Monitoring plan:

– Clinical: cognition (repeat MoCA), mood, function, falls, adherence.

– Laboratory: BP, HbA1c, lipids, U&E/eGFR (especially with intensive BP control, metformin, SGLT2i), homocysteine/B12 if supplementing, LFTs and platelets if any experimental agent used.

– Ageing/AD biomarkers: serial plasma p-tau217/NfL may track trajectory in higher-risk patients but should not drive treatment decisions in isolation until better validated.[5][36]

Timepoints: short-term 4–12 weeks (tolerability, BP, glucose); medium-term 6–12 months (risk factors, cognition, adherence); long-term annually (cognition, biomarkers, MRI if indicated).

Adverse effects / actions:

– Intensive BP lowering: hypotension, syncope, AKI, electrolyte disturbance — reduce intensity if symptomatic or eGFR falls.

– B vitamins: generally well tolerated; high-dose folate can mask B12 deficiency.

– GLP-1RA: GI effects, weight loss (caution in frailty/sarcopenia), rare pancreatitis, gallbladder disease.

– Senolytics (research): cytopenias, thrombocytopenia — mandatory FBC monitoring; stop for haematological toxicity.[6]

– Rapamycin (research): immunosuppression, stomatitis, dyslipidaemia, glucose intolerance.

Interactions: polypharmacy in older/frail patients; avoid stacking multiple experimental agents; review anticholinergic/sedative burden which itself impairs cognition.

Special populations: pregnancy/breastfeeding — avoid off-label geroscience agents (rapamycin, senolytics contraindicated); renal/hepatic impairment — dose-adjust or avoid metformin/GLP-1RA per label; frailty and extremes of age — favour conservative BP targets, prioritise exercise, sensory and sleep optimisation over pharmacology.

8. Contraindications and cautions

– Absolute: pregnancy/breastfeeding for rapamycin and senolytics; active malignancy or serious infection for immunosuppressive agents; known hypersensitivity.

– Relative / specialist advice: significant frailty or orthostatic hypotension (intensive BP targets); advanced CKD (metformin, some GLP-1RA); active thrombocytopenia or bleeding risk (senolytics); complex polypharmacy.

– Harm likely to outweigh benefit with current evidence: routine vitamin D or omega-3 supplementation for cognition in replete adults; any off-label geroscience agent used specifically for cognition outside a research/consent framework, given absence of human efficacy data.[28][30]

9. Practical management scenarios

Scenario A — Middle-aged patient with multiple cardiometabolic risk factors. Offer (strong).

– Assessment: full vascular/metabolic panel, homocysteine, APOE (with counselling), baseline cognition; consider plasma p-tau217 only if SCD present.

– Shared decision-making: emphasise that multidomain lifestyle and vascular risk control have the strongest evidence.

– Initiation: FINGER-style multidomain programme; treat BP, lipids, glucose to guideline targets (consider intensive BP with monitoring); smoking cessation; structured exercise; correct any elevated homocysteine with B vitamins.

– Monitoring: risk factors and cognition at 6–12 months.

– Escalate/refer: refer to memory services if objective decline emerges.

Scenario B — Older, frail patient with multimorbidity. Consider, with restriction.

– Prioritise low-risk, high-value measures: exercise adapted to capacity, hearing aids, sleep and mood optimisation, deprescribing anticholinergics/sedatives.

– Avoid: aggressive BP targets, high supplement/experimental drug burden.

– Consent: emphasise falls and hypotension risks; individualise.

– Monitor: falls, BP, function; de-escalate if adverse effects.

Scenario C — Adjunct to conventional specialist care. Offer lifestyle; restrict experimental agents to research.

– For a patient with T2D/obesity already on specialist care, GLP-1RA for its licensed metabolic indication is reasonable, with cognitive benefit as a plausible ancillary effect (off-label if used for cognition).[31][32]

– Coordinate with the treating specialist; do not duplicate or counteract prescribed therapy.

– Keep senolytics, NAD⁺ precursors and rapamycin within trials/registries only.

The SMARRT RCT illustrates that a personalised, multidomain risk-reduction programme produced a statistically significant cognitive benefit versus control over 2 years.

10. Research gaps and future directions

– Whether multidomain and single-factor interventions reduce dementia incidence (not just cognitive composites) with longer follow-up; World-Wide FINGERS and US POINTER will help.[38][3]

– Optimal, personalised protocols for APOE ε4 carriers and by biomarker status.[10]

– Whether GLP-1RA and SGLT2i prevent dementia in non-diabetic populations; dedicated AD RCTs (e.g. evoke/evoke+) are reporting.[33][31]

– Human efficacy, dosing, long-term safety and washout effects of geroscience agents — metformin (TAME-type frailty/healthspan trials), NAD⁺ precursors, senolytics, rapamycin — which currently lack cognitive-outcome RCTs and should remain research-only.[8][13]

– Standardisation and validation of plasma biomarkers (p-tau217, NfL, GFAP) for asymptomatic screening and as monitoring/surrogate endpoints.[5][36]

– Establishing whether biomarker or brain-atrophy changes translate into hard clinical benefit — the B-vitamin/atrophy literature shows this linkage is not assured.[26][24]

References

1. FDA Orange Book. FDA Orange Book.
2. Blood Biomarkers in Neurodegenerative Diseases: Implications for the Clinical Neurologist. Alcolea D, Beeri MS, Rojas JC, Gardner RC, Lleó A. Neurology. 2023;101(4):172-180. doi:10.1212/WNL.0000000000207193.
3. Vascular Contributions to Cognitive Impairment and Brain Health: Clinical Update and Mechanistic Considerations: A Scientific Statement From the American Heart Association. Sorond FA, Gorelick PB, Bae HJ, et al. Stroke. 2026;57(7):e254-e270. doi:10.1161/STR.0000000000000524.
4. An Ounce of Prevention: The Growing Need for Preventive Neurologists. Sabayan B, Boden-Albala B, Rost NS. Neurology. 2025;105(1):e213785. doi:10.1212/WNL.0000000000213785.
5. Blood-Based Biomarkers for Alzheimer’s Disease: Advances in Early Detection and Monitoring of Age-Related Neurodegeneration. Fu W, Ho PC. Ageing Research Reviews. 2026;117:103058. doi:10.1016/j.arr.2026.103058.
6. Pharmacological Targeting of Senescence With Senolytics as a New Therapeutic Strategy for Neurodegeneration. Richardson M, Richardson DR. Molecular Pharmacology. 2024;105(2):64-74. doi:10.1124/molpharm.123.000803.
7. Senolytics as Modulators of Critical Signaling Pathways: A Promising Strategy to Combat Brain Aging and Neurodegenerative Disorders. Singh I, Singh AK. Molecular Neurobiology. 2025;63(1):261. doi:10.1007/s12035-025-05504-1.
8. Drugs Targeting Mechanisms of Aging to Delay Age-Related Disease and Promote Healthspan: Proceedings of a National Institute on Aging Workshop. Espinoza SE, Khosla S, Baur JA, de Cabo R, Musi N. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences. 2023;78(Suppl 1):53-60. doi:10.1093/gerona/glad034.
9. Immunomodulatory and Antiaging Mechanisms of Resveratrol, Rapamycin, and Metformin: Focus on mTOR and AMPK Signaling Networks. Sorrenti V, Benedetti F, Buriani A, et al. Pharmaceuticals (Basel, Switzerland). 2022;15(8):912. doi:10.3390/ph15080912.
10. A Multimodal Framework for Alzheimer’s Prevention: Diet, Exercise, Fasting, Sleep, and Gut Microbiota. Kurmi S, Shirodkar S, Parab SB, Doshi G. Current Alzheimer Research. 2026;:CAR-EPUB-155237. doi:10.2174/0115672050467997260323164241.
11. NAD+ Supplementation Reduces Neuroinflammation and Cell Senescence in a Transgenic Mouse Model of Alzheimer’s Disease via cGAS-STING. Hou Y, Wei Y, Lautrup S, et al. Proceedings of the National Academy of Sciences of the United States of America. 2021;118(37):e2011226118. doi:10.1073/pnas.2011226118.
12. Compounds That Extend Longevity Are Protective in Neurodegenerative Diseases and Provide a Novel Treatment Strategy for These Devastating Disorders. Soo SK, Rudich PD, Traa A, et al. Mechanisms of Ageing and Development. 2020;190:111297. doi:10.1016/j.mad.2020.111297.
13. Effects of Lifespan-Extending Interventions on Cognitive Healthspan. Culig L, Sahbaz BD, Bohr VA. Expert Reviews in Molecular Medicine. 2022;25:e2. doi:10.1017/erm.2022.36.
14. Some Naturally Occurring Compounds That Increase Longevity and Stress Resistance in Model Organisms of Aging. Gómez-Linton DR, Alavez S, Alarcón-Aguilar A, et al. Biogerontology. 2019;20(5):583-603. doi:10.1007/s10522-019-09817-2.
15. A 2 Year Multidomain Intervention of Diet, Exercise, Cognitive Training, and Vascular Risk Monitoring Versus Control to Prevent Cognitive Decline in at-Risk Elderly People (FINGER): A Randomised Controlled Trial. Ngandu T, Lehtisalo J, Solomon A, et al. Lancet (London, England). 2015;385(9984):2255-63. doi:10.1016/S0140-6736(15)60461-5.
16. Effect of Personalized Risk-Reduction Strategies on Cognition and Dementia Risk Profile Among Older Adults: The SMARRT Randomized Clinical Trial. Yaffe K, Vittinghoff E, Dublin S, et al. JAMA Internal Medicine. 2024;184(1):54-62. doi:10.1001/jamainternmed.2023.6279.
17. The Relationships Between Physical Activity, Sedentary Behaviour, Sleep, and Dementia: A Systematic Review and Meta-Analysis of Cohort Studies. Oye-Somefun A, Mirzadeh P, Gao-Kang J, et al. PloS One. 2026;21(4):e0343621. doi:10.1371/journal.pone.0343621.
18. Association of Hearing Aids and Cochlear Implants With Cognitive Decline and Dementia. Yeo BSY, Song HJJMD, Toh EMS, et al. JAMA Neurology. 2023;80(2):134-141. doi:10.1001/jamaneurol.2022.4427.
19. Treating Hearing Loss With Hearing Aids for the Prevention of Cognitive Decline and Dementia. Cribb L, Moreno-Betancur M, Pase MP, et al. Neurology. 2026;106(3):e214572. doi:10.1212/WNL.0000000000214572.
20. Hearing Loss, Hearing Aid Use, and Risk of Dementia in Older Adults. Cantuaria ML, Pedersen ER, Waldorff FB, et al. JAMA Otolaryngology– Head & Neck Surgery. 2024;150(2):157-164. doi:10.1001/jamaoto.2023.3509.
21. Dementia Prevention and Treatment. Reuben DB, Kremen S, Maust DT. JAMA Internal Medicine. 2024;184(5):563-572. doi:10.1001/jamainternmed.2023.8522.
22. Healthy Lifestyle and the Risk of Alzheimer Dementia: Findings From 2 Longitudinal Studies. Dhana K, Evans DA, Rajan KB, Bennett DA, Morris MC. Neurology. 2020;95(4):e374-e383. doi:10.1212/WNL.0000000000009816.
23. B Vitamins and Prevention of Cognitive Decline and Incident Dementia: A Systematic Review and Meta-Analysis. Wang Z, Zhu W, Xing Y, Jia J, Tang Y. Nutrition Reviews. 2022;80(4):931-949. doi:10.1093/nutrit/nuab057.
24. Homocysteine-Lowering by B Vitamins Slows the Rate of Accelerated Brain Atrophy in Mild Cognitive Impairment: A Randomized Controlled Trial. Smith AD, Smith SM, de Jager CA, et al. PloS One. 2010;5(9):e12244. doi:10.1371/journal.pone.0012244.
25. Prevention of Sporadic Alzheimer’s Disease: Lessons Learned From Clinical Trials and Future Directions. Andrieu S, Coley N, Lovestone S, Aisen PS, Vellas B. The Lancet. Neurology. 2015;14(9):926-944. doi:10.1016/S1474-4422(15)00153-2.
26. High-Dose B Vitamin Supplementation and Cognitive Decline in Alzheimer Disease: A Randomized Controlled Trial. Aisen PS, Schneider LS, Sano M, et al. JAMA. 2008;300(15):1774-83. doi:10.1001/jama.300.15.1774.
27. The Relationship of Omega-3 Fatty Acids With Dementia and Cognitive Decline: Evidence From Prospective Cohort Studies of Supplementation, Dietary Intake, and Blood Markers. Wei BZ, Li L, Dong CW, Tan CC, Xu W. The American Journal of Clinical Nutrition. 2023;117(6):1096-1109. doi:10.1016/j.ajcnut.2023.04.001.
28. Effect of Vitamin D Supplementation, Omega-3 Fatty Acid Supplementation, or a Strength-Training Exercise Program on Clinical Outcomes in Older Adults. Bischoff-Ferrari HA, Vellas B, Rizzoli R, et al. JAMA. 2020;324(18):1855-1868. doi:10.1001/jama.2020.16909.
29. Over-the-Counter Supplement Interventions to Prevent Cognitive Decline, Mild Cognitive Impairment, and Clinical Alzheimer-Type Dementia: A Systematic Review. Butler M, Nelson VA, Davila H, et al. Annals of Internal Medicine. 2018;168(1):52-62. doi:10.7326/M17-1530.
30. Effect of Vitamin D on Cognitive Decline: Results From Two Ancillary Studies of the VITAL Randomized Trial. Kang JH, Vyas CM, Okereke OI, et al. Scientific Reports. 2021;11(1):23253. doi:10.1038/s41598-021-02485-8.
31. Cardioprotective Glucose-Lowering Agents and Dementia Risk. Seminer A, Mulihano A, O’Brien C, et al. JAMA Neurology. 2025;82(5):450-460. doi:10.1001/jamaneurol.2025.0360.
32. GLP-1RA and SGLT2i Medications for Type 2 Diabetes and Alzheimer Disease and Related Dementias. Tang H, Donahoo WT, DeKosky ST, et al. JAMA Neurology. 2025;82(5):439-449. doi:10.1001/jamaneurol.2025.0353.
33. Efficacy and Safety of Oral Semaglutide 14 Mg (Flexible Dose) in Early-Stage Symptomatic Alzheimer’s Disease (Evoke and Evoke+): Two Phase 3, Randomised, Placebo-Controlled Trials. Cummings JL, Atri A, Sano M, et al. Lancet (London, England). 2026;407(10544):2167-2179. doi:10.1016/S0140-6736(26)00459-9.
34. Pharmacological Approaches to Decelerate Aging: A Promising Path. Hassani B, Goshtasbi G, Nooraddini S, Firouzabadi N. Oxidative Medicine and Cellular Longevity. 2022;2022:4201533. doi:10.1155/2022/4201533.
35. Association of Healthy Lifestyles With Risk of Alzheimer Disease and Related Dementias in Low-Income Black and White Americans. Yang JJ, Keohane LM, Pan XF, et al. Neurology. 2022;99(9):e944-e953. doi:10.1212/WNL.0000000000200774.
36. The Role of Clinical, Plasma, and Imaging Biomarkers in Assessing Future Dementia Risk in Individuals With Subjective Cognitive Decline. Rivera Sánchez M, Mastenbroek SE, Janelidze S, et al. Neurology. 2026;106(11):e214983. doi:10.1212/WNL.0000000000214983.
37. Circulating Biomarkers of Neurodegeneration and Risk of Cognitive Impairment. Sawyer RP, Bennett A, Blair J, et al. Neurology. 2025;105(4):e213935. doi:10.1212/WNL.0000000000213935.
38. World-Wide FINGERS Network: A Global Approach to Risk Reduction and Prevention of Dementia. Kivipelto M, Mangialasche F, Snyder HM, et al. Alzheimer’s & Dementia : The Journal of the Alzheimer’s Association. 2020;16(7):1078-1094. doi:10.1002/alz.12123.